| Popis: |
We have investigated in preliminary pilot studies the therapeutic action of a new GABA-mimetic compound, SL 76 002, in neurological and psychiatric syndromes. The compound was administered in daily oral doses of 450–2400 mg for 2 weeks to 8 months, (a) SL 76 002 showed a beneficial effect in 17 out of 30 patients suffering from severe epilepsy (generalized and partial seizures) non responding to pharmacological treatment, (b) SL 76 002 given alone or in association with neuroleptics to 26 schizophrenic patients did not elicit any significant clinical effect, (c) In Huntington chorea (26 cases), neurological symptomes and mood were improved in some patients; the results, however, were rather variable, (d) SL 76 002 had a definite effect in spastic syndromes (21 cases), (e) The compound administered to 15 depressed patients showed an antidepressant action which appeared in most of the cases within the first 3–8 days of the treatment. These preliminary results suggest involvement of GABA in the pathophysiology of neuropsychiatric disorders. |
